Evidence map›Paper›PMID 28093569›Full record

ArticleMolecular psychiatry2018

Translational evaluation of translocator protein as a marker of neuroinflammation in schizophrenia.

T Notter, J M Coughlin, T Gschwind, U Weber-Stadlbauer, Y Wang, M Kassiou, A C Vernon, D Benke, M G Pomper, A Sawa and 1 more

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Molecular psychiatry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 120 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
120citing papers in PubMed, 3 pooled it
10.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

120 citing papers in PubMed, 3 syntheses or guidelines pooled it, 189 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Review
  7. Evidence for brain glial activity in chronic migraine patients: a [European journal of nuclear medicine and molecular imaging · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. In vivo translocator protein in females with autism spectrum disorder: a pilot study.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024
    Article
  17. Article
  18. Review
  19. Review
  20. Article

60 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 4 countries.

T NotterInstitute of Pharmacology and Toxicology, University of Zurich-Vetsuisse, Zurich, Switzerland.
J M CoughlinDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
T GschwindNeuroscience Center Zurich, University of Zurich and ETH Zurich, Zurich, Switzerland.
U Weber-StadlbauerInstitute of Pharmacology and Toxicology, University of Zurich-Vetsuisse, Zurich, Switzerland.
Y WangRussell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
M KassiouSchool of Chemistry, The University of Sydney, Sydney, NSW, Australia.
A C VernonMRC Centre for Neurodevelopmental Disorders, King's College London, London, UK.
D BenkeNeuroscience Center Zurich, University of Zurich and ETH Zurich, Zurich, Switzerland.
M G PomperDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
A SawaDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
U MeyerInstitute of Pharmacology and Toxicology, University of Zurich-Vetsuisse, Zurich, Switzerland.
Johns Hopkins University · USUniversity of Zurich · CHETH Zurich · CHKing's College London · GBUniversity of Sydney · AU

Funding

Medical Research Council MR/N025377/1Medical Research Council MR/N026063/1
6 · The paper itself

Abstract

Positron emission tomography (PET) imaging with radiotracers that target translocator protein 18 kDa (TSPO) has become a popular approach to assess putative neuroinflammatory processes and associated microglia activation in psychotic illnesses. It remains unclear, however, whether TSPO imaging can accurately capture low-grade inflammatory processes such as those present in schizophrenia and related disorders. Therefore, we evaluated the validity of TSPO as a disease-relevant marker of inflammation using a translational approach, which combined neurodevelopmental and neurodegenerative mouse models with PET imaging in patients with recent-onset schizophrenia and matched controls. Using an infection-mediated neurodevelopmental mouse model, we show that schizophrenia-relevant behavioral abnormalities and increased inflammatory cytokine expression are associated with reduced prefrontal TSPO levels. On the other hand, TSPO was markedly upregulated in a mouse model of acute neurodegeneration and reactive gliosis, which was induced by intrahippocampal injection of kainic acid. In both models, the changes in TSPO levels were not restricted to microglia but emerged in various cell types, including microglia, astrocytes and vascular endothelial cells. Human PET imaging using the second-generation TSPO radiotracer [

Indexed as

AdultAnimalsAstrocytesBiomarkersDisease Models, AnimalFemaleHumansInflammationMaleMiceMice, Inbred C57BLMicrogliaNeuroimmunomodulationPositron-Emission TomographyReceptors, GABASchizophreniaBiomarkersBzrp protein, mouseReceptors, GABATSPO protein, human

Identifiers

PMID28093569
OpenAlexW2577286614

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.